Background: Fibrosis development in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and limited sample size hinder the identification of consistent and targetable fibrogenic mechanisms. Methods: To identify conserved fibrogenic mechanisms, we performed a comprehensive meta-analysis of hepatic transcriptomic data with fibrosis stage characterized from ~1000 patients with MASLD. Results: Our meta-analysis revealed 846 differentially regulated genes associated with fibrosis progression (F3–4 vs. F0–1). Pathway analysis showed that these genes are involved in matrix organization (THBS2, ADAMTSL2), inflammation (CXCL6, CCL19), solute transport (SLC13A5, SLC16A10), and metabolism (AADAT, GRAMD1B). scRNA-seq-based deconvolution revealed increased proportions of immune (CD4+ T cells), endothelial (HA endo cells), and mesenchymal (myofibroblasts) cell types, and loss of LSECs in patients with advanced fibrosis in the meta-analysis. Finally, analysis of ligand–receptor pairs identified putative cell–matrix interactions (MMP7–CDH6), cell signaling (PDGFD–PDGFRA), and immune cell interactions (ANXA1–FPR1) associated with fibrosis conserved across multiple datasets and enriched in patients with fibrosis. Conclusions: We identified conserved transcriptomic changes and gene networks in patients with advanced fibrosis, as well as putative ligand–receptor interactions that facilitate cell–cell interactions that drive fibrosis. These findings will inform mechanistic studies and the development of anti-fibrotic therapies.
The critically re-evaluated human liver single-nucleus RNA-sequencing data using a rigorous per-donor statistical framework to dissociate invariant biological signals from technical artifacts and establish a reproducibility-first standard for single-cell translational research.
H. Ling, P. Qiu, Yan-Zhu Hu· International Journal of Mol...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is biologically heterogeneous and lacks sufficiently validated molecular biomarkers for disease characterization. Post-translational modification (PTM)-related genes may link metabolic stress to lipid dysregulation and inflammation, but their relevance...
A validated machine-learning -derived transcriptomic signature that reflects the immune-stromal dynamics of renal fibrosis and implicates B-cell-mediated fibroblast activation as a promising diagnostic biomarker and a potential therapeutic target is presented.
S. Fazeli, A. Javanmard· Iranian journal of immunolog...· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood.
METHODS
We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core...
Yan Wang, Shuang-Shuang Lu· Frontiers in Bioscience· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD), the leading cause of chronic liver pathologies worldwide, represents a growing clinical burden. Its diagnosis remains reliant on liver biopsy that limits early detection and the ability to capture molecular changes across disease progression. A systemati...
Eren Kumak, Thomas Darde, Ozlen Konu· bioRxiv· 0 citations
This chapter offers a comprehensive, reproducible protocol for identifying and clinically validating circulating long noncoding RNA (lncRNA) biomarkers for NAFLD and NASH.
M. A. Hussein, Anwar Abdelnaser· Methods in molecular biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.